The Biden administration has chosen the first 10 medications up for price negotiation under the Medicare program, marking a major step toward tackling the skyrocketing cost of prescription pharmaceuticals.
This program represents a significant advancement in the administration’s mission to improve access to and affordability of healthcare for all Americans. Some of the most costly and often prescribed prescriptions in the US are on the list of drugs up for negotiation, such as insulin, cancer therapies, and meds for rheumatoid arthritis and multiple sclerosis.
Due to their expensive prices, which sometimes put them out of reach for many Medicare recipients, these medications have been the subject of much public outrage. By using Medicare’s buying power, which provides healthcare for millions of seniors and individuals with disabilities, this effort seeks to reduce prescription costs.
Medicare is not permitted by existing legislation to bargain directly for reduced prescription pricing with manufacturers. The Medicare Prescription Drug Price Negotiation Act, which enables discussions on behalf of Medicare patients, was put into place by the Biden administration in an effort to reverse that.
Read Also: Federal Reserve Chairman Signals Further Rate Increases
The Medicare Price Negotiation Debate
It is impossible to emphasize how high medicine costs affect American households. Many people, especially elderly people on limited incomes, are compelled to choose between buying basic essentials like food and medicine.
The Biden administration hopes to lessen this burden and enhance the general health and wellbeing of Medicare enrollees by addressing the cost of these essential medications. Those opposed to Medicare’s power to negotiate drug costs contend that doing so may hinder innovation and restrict access to novel treatments.
Advocates claim that it is feasible to reconcile cost with ongoing pharmaceutical research and development. The Biden administration’s healthcare policy has reached a major turning point with this statement, but there are still obstacles to overcome.
Pharmaceutical firms, healthcare organizations, and the government all participate in the complicated process of negotiating medication costs.
Read Also: Beijing’s Crackdown Wounds Evergrande: Shares Plunge Over 99% in Three Years
Source: www.cnbc.com
